Skip to main content

Table 2 Baseline characteristics of subgroups of non-PCOS and PCOS without HA participants

From: PCOS without hyperandrogenism is associated with higher plasma Trimethylamine N-oxide levels

 

Control

PCOS-N

BMI < 24

BMI ≥ 24

BMI < 24

BMI ≥ 24

n

11

12

11

16

Age (years)

27.00 (26.00–29.00)

26.50 (22.5–28.75)

26.00 (24.00–29.00)

27.00 (25.50–29.75)

BMI (kg/m2)

21.23 (19.35–22.20)

27.39 (25.99–28.90)a

20.83 (19.20–22.58)b

27.19 (24.65–29.59) ac

LH (IU/L)

5.21 (4.21–5.63)

6.16 (5.00–11.13)

8.72 (6.67–15.23)

11.33 (7.26–20.24)a

FSH (IU/L)

6.96 (5.32–9.36)

6.28 (5.97–7.41)

5.43 (3.20–8.51)

5.82 (3.60–7.17)

LH/FSH

0.79 (0.60–0.91)

1.01 (0.82–1.54)

1.62 (1.33–2.42)a

1.90 (1.36–2.87)ab

P (nmol/L)

0.70 (0.60–0.91)

0.52 (0.37–0.98)

0.77 (0.45–1.75)

0.51 (0.38–0.88)

E2 (pmol/L)

130.80 (94.00–175.40)

168.65 (132.85–381.08)

230.00 (120.40–585.30)

159.70 (108.4–235.35)

T (nmol/L)

1.10 (0.61–1.37)

0.90 (0.76–1.59)

1.37 (1.09–1.56)

1.18 (0.95–1.40)

FT (pmol/L)

7.42 (5.95–9.93)

6.92 (6.51–10.11)

6.01 (4.93–10.45)

9.99 (6.71–13.34)

FBG (mmol/L)

5.60 (5.20–6.00)

5.70 (5.05–5.98)

5.80 (5.60–6.30)b

6.10 (5.70–6.58)

FINS (μIU/ml)

8.99 (7.40–10.80)

16.88 (12.53–20.51)a

12.78 (8.98–14.65)

15.79 (11.95–30.87)a

HOMA-IR

2.38 (1.91–2.59)

3.98 (3.00–5.22)a

3.57 (2.27–3.65)

4.16 (3.15–8.99)a

Cr (μmol/L)

64.40 (59.00–66.20)

64.30 (61.08–66.50)

59.70 (56.20–69.00)

64.95 (63.50–67.28)

CRP (mg/L)

1.02 (0.46–2.61)

1.56 (1.06–3.16)

0.84 (0.20–1.37)

2.15 (1.53–5.58)ac

CHOL (mmol/L)

4.80 (4.01–5.34)

4.75 (4.31–5.11)

4.41 (3.96–4.81)

5.11 (4.69–6.01)

TG (mmol/L)

1.03 (0.90–1.24)

1.01 (0.80–1.86)

0.81 (0.60–1.43)

1.53 (1.13–2.24)

ALT (U/L)

13.00 (8.00–19.00)

24.00 (18.25–35.00)

15.00 (10.00–21.00)

28.00 (15.75–36.25)ac

AST (U/L)

16.00 (13.00–17.00)

20.00 (16.25–28.00)a

17.00 (15.00–22.00)

20.00 (16.50–21.75)

HDL (mmol/L)

1.42 (1.27–1.59)

1.40 (1.23–1.59)

1.63 (1.31–1.85)

1.25 (1.13–1.51)

LDL (mmol/L)

2.72 (2.28–3.49)

2.77 (2.26–3.38)

2.44 (1.90–3.01)

2.85 (2.52–3.39)

sdLDL (mmol/L)

0.87 (0.73–1.06)

0.84 (0.60–1.17)

0.77 (0.57–0.95)

1.18 (0.76–1.54)

APOA (g/L)

1.40 (1.21–1.64)

1.35 (1.26–1.63)

1.46 (1.33–1.57)

1.38 (1.30–1.53)

APOB (g/L)

0.73 (0.64–0.80)

0.72 (0.62–0.83)

0.65 (0.54–0.71)

0.78 (0.64–0.87)

  1. Data are presented as median (interquartile range). aP < 0.05 versus control-normal weight participants, bP < 0.05 versus control-obese weight participants, cP < 0.05 versus PCOS-normal weight participants. BMI Body mass index, LH Luteinizing hormone, FSH Follicle-stimulating hormone, P Progesterone, E2 Estradiol, T Testosterone, FT Free testosterone, FBG Fasting blood glucose, FINS Fasting plasma insulin, HOMA-IR Homeostasis model assessment insulin resistance index, Cr Creatinine, CRP C-reactive protein, CHOL Cholesterol, TG Triglyceride, ALT Alanine transaminase, AST Aspartate aminotransferase, LDL Low-density lipoprotein, HDL High-density lipoprotein, sdLDL Small dense LDL, APOA Apolipoprotein A, APOB apolipoprotein B
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us